Methotrexate Pfizer

Methotrexate, the active ingredient in Methotrexate Pfizer, is an antimetabolite presented as an unknown/unknown for intra‑arterial, intramuscular, and intravenous use. It is employed to treat rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and gestational trophoblastic disease in appropriate patients.

GNH USA supplies Methotrexate Pfizer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Methotrexate is an antimetabolite used across several disease families, notably inflammatory and malignant conditions. - Rheumatoid arthritis: reduces disease activity and joint inflammation. - Psoriasis: decreases skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with leukemic cell proliferation. - Non‑Hodgkin lymphoma: limits growth of malignant lymphocytes. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting. - Fatigue or malaise. - Mouth sores (stomatitis). - Mild elevation of liver enzymes. - Temporary hair thinning.

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Bone marrow suppression leading to pancytopenia. - Acute renal impairment. - Life‑threatening infections due to immunosuppression.

When using Methotrexate, careful monitoring and patient education are essential. - Renal function: assess before initiation and periodically thereafter. - Liver health: perform baseline and regular liver function tests. - Hematology: monitor complete blood counts to detect bone‑marrow suppression. - Pregnancy and lactation: avoid use in pregnancy and advise effective contraception; discontinue if pregnancy occurs. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Methotrexate interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins and other β‑lactam antibiotics: may raise serum methotrexate levels. - Sulfonamide antibiotics: can potentiate adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Azathioprine or other immunosuppressants: increased risk of bone‑marrow suppression. - Proton pump inhibitors: may affect renal clearance, watch renal function.